Sign in
Taking people in United StatesNo phase

Following people with progressive multifocal leukoencephalopathy to study how the disease develops

Observes people with a brain infection caused by JC virus over time.

Key facts

Who runs it
National Institute of Neurological Disorders and Stroke (NINDS)
Where
Bethesda, United StatesSee the site
Trial code
Registry title
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Status
Recruiting
People taking part
700 people, planned
Started
8 Nov 2012
Expected to end
1 Jan 2052
Type of study
Observational, 3 groups
Record updated
29 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with suspected or confirmed PML, a serious brain infection caused by JC virus. It also takes people at risk of PML and healthy volunteers.

Age
PML patients and at-risk controls: at least 2 years old. Healthy volunteers: at least 18 years old.
Sex
All sexes can join.
Disease stage
PML patients need suspected or confirmed PML and an MRI that fits PML. Control patients have weak immune function and are at risk for PML.
Earlier treatment
No specific prior treatment is asked for. Control patients may have a history of treatment that weakens or changes the immune system.

Main reasons for not taking part

  • Pregnancy
  • Medical reason not to have an MRI, such as a pacemaker, infusion pump or metal implants
  • A serious condition that makes the study tests impossible or risky, in the investigator's judgment
  • Cannot give informed consent, directly or through a legal representative
  • Unwilling to give biological samples or have them stored frozen

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Suspected or confirmed PML
  • MRI compatible with PML
  • Able to participate in the studies and follow-up required by the protocol
  • At least 2 years old
  • Able to participate in the studies and follow-up required by the protocol
  • At least 2 years old
  • Impaired immune function from any cause and considered at risk for PML (i.e.-history of hematological malignancy, chronic inflammatory disease, history of treatment with immune suppressive or immunomodulatory therapies, primary or acquired immunodeficiency syndromes)
  • Able to participate in the studies and follow-up required by the protocol
  • At least 18 years old

Who cannot take part

  • Impaired immune function (i.e.-history of hematological malignancy, chronic inflammatory disease, history of treatment with immune suppressive or immunomodulatory therapies, primary or acquired immunodeficiency syndromes)
  • Significant condition, which in the judgment of the principal investigator, would make participation in the diagnostic and research parts of evaluation impossible or risky
  • Medical contraindication to MRI (i.e., devices such as a cardiac pacemaker or infusion pump, other metallic implants, metallic foreign objects, body piercings that cannot be removed)
  • Significant condition, which in the judgment of the principal investigator, would make participation in the diagnostic and research parts of evaluation impossible or risky
  • Medical contraindication to MRI (i.e., devices such as a cardiac pacemaker or infusion pump, other metallic implants, metallic foreign objects, body piercings that cannot be removed)
  • Significant condition, which in the judgment of the principal investigator, would make participation in the diagnostic and research parts of evaluation impossible or risky
  • Medical contraindication to MRI (i.e., devices such as a cardiac pacemaker or infusion pump, other metallic implants, metallic foreign objects, body piercings that cannot be removed)
  • Pregnancy
  • Inability to provide informed consent, either directly or via legally authorized representative (LAR)
  • Unwillingness to consent for collection of biological samples or their cryopreservation; Control Patients at Risk for PML
  • Pregnancy
  • Inability to provide informed consent, either directly or via legally authorized representative (LAR)
  • Unwillingness to consent for collection of biological samples or their cryopreservation; Healthy Volunteers
  • Pregnancy
  • Inability to provide informed consent, either directly or via legally authorized representative (LAR)
  • Unwillingness to consent for collection of biological samples or their cryopreservation

Other criteria

  • PML Patients

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 2 and 120 years old?

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United StatesContact: Mauricio A CampillayTaking people

About the trial

What the trial wants to find out

Background:

Read full original descriptionShow less

- Progressive multifocal leukoencephalopathy (PML) is a severe viral infection of the brain. It is caused by JC virus. Many people have this virus in their bodies all their life, but it is usually kept in check by their immune system. If the immune system does not work right because of a disease or medication, the virus becomes active and can damage cells in the brain. Not much is known about PML or how it affects the immune system. Researchers want to study people with PML to better understand the natural history of the disease.

Objectives:

- To study the natural history of PML.

Eligibility:

- Individuals at least 2 years of age who have PML.

Design:

* Participants will be screened with a physical exam, medical history, and imaging studies. * Participants will have several visits to the National Institutes of Health Clinical Center. There will be an initial visit, monthly visits for the next 6 months, a 12-month visit, and possible visits afterward. * At the initial visit, participants will give blood, urine, and spinal fluid samples. They will also have neurological tests and imaging studies of the brain. * For the next five visits, participants will give blood and urine samples. They will also have neurological tests and imaging studies of the brain. * The 6-month and 12-month visits will repeat the tests from the initial visit. * Other optional procedures include bone marrow samples and skin biopsies. Additional blood tests and imaging studies may be performed. * Treatment will not be provided as part of this study.

The 3 groups in the trial

  • Control Patients at Risk for PML

    Participants with impaired immune function from any cause and considered at risk for PML

  • Healthy Volunteers

    Healthy volunteers without impaired immune function

  • PML Patients

    Participants with PML

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Plain-language title
Following people with progressive multifocal leukoencephalopathy to study how the disease developsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT01730131, who can take part
Record updated
29 October 2026